New treatment modalities in advanced thyroid cancer

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 10-18

  Kapiteijn, E ^a   Schneider, T C ^a   Morreau, H ^a   Gelderblom, H ^a   Nortier, J W R ^a   Smit, J W A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Molecular pathogenesis; New treatment modalities; Thyroid cancer

Indexed keywords

AXITINIB; B RAF KINASE; CABOZANTINIB; CAPECITABINE; DACARBAZINE; DEPSIPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IODINE 131; LENVATINIB; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; RETINOIC ACID; SELUMETINIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TIPIFARNIB; TROGLITAZONE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VEMURAFENIB; VORINOSTAT;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CONSTIPATION; DEACETYLATION; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GENE THERAPY; HAND FOOT SYNDROME; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IC 50; INOPERABLE CANCER; MEDULLARY CARCINOMA; METASTASIS POTENTIAL; METHYLATION; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; NONMEDULLARY THYROID CANCER; OVERALL SURVIVAL; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; REVIEW; RHYTHM DISORDER; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84855179237     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr117     Document Type: Review

References (105)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society 2007.
2. Hay ID, Klee GG. Thyroid cancer diagnosis and management. Clin Lab Med 1993; 13: 725-734.
3. Schlumberger M, Pacini F. Thyroid tumors. Paris, France: Editions Nucléon 2006.
4. Mitsutake N, Knauf JA, Mitsutake S et al. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005; 65: 2465-2473.
5. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-262.
6. Kebebew E, Weng J, Bauer J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246: 466-470.
7. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003; 12: 69-90.
8. Puxeddu E, Durante C, Avenia N et al. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 2008; 19: 138-145.
9. Cohen Y, Xing M, Mambo E et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625-627.
10. Ringel MD, Hayre N, Saito J et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001; 61: 6105-6111.
11. Miyakawa M, Tsushima T, Murakami H et al. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 2003; 50: 77-83.
12. Vasko V, Saji M, Hardy E et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004; 41: 161-170.
13. Kada F, Saji M, Ringel MD. Akt: a potential target for thyroid cancer therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 181-185.
14. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008; 113: 2440-2447.
15. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007; 96: 16-20.
16. Soh EY, Duh QY, Sobhi SA et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997; 82: 3741-3747.
17. Kimura ET, Nikiforova MN, Zhu Z et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457.
18. Schilling T, Burck J, Sinn HP et al. Prognostic value of codon 918 (ATG->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001; 95: 62-66.
19. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML et al. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol 2005; 29: 544-549.
20. Ivan M, Bond JA, Prat M et al. Activated ras and ret oncogenes induce overexpression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997; 14: 2417-2423.
21. Kogan EA, Rozhkova EB, Seredin VP et al. [Prognostic value of the expression of thyreoglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemical studies]. Arkh Patol 2006; 68: 8-11.
22. Pennell NA, Daniels GH, Haddad RI et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18: 317-323.
23. Banerji U, Camidge DR, Verheul HM et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16: 1613-1623.
24. Lucas A, Cohen EE, Cohen RB et al. Phase II study and tissue correlative studies of AZD 6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J.Clin.Oncol. 2010; 28 (Suppl): 15s (Abstr 5536).
25. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474-5483.
26. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26: 4708-4713.
27. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 2369-2376.
28. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
29. Schlumberger M, Elisei R, Bastholt L et al. Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27: 3794-3801.
30. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62: 7284-7290.
31. Wells SA, Jr., Gosnell JE, Gagel RF et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28: 767-772.
32. Robinson BG, Paz-Ares L, Krebs A et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2664-2671.
33. Wells SA, Robinson BG, Gagel R.F et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). J.Clin.Oncol. 2010; 28 (Suppl): 15s (Abstr 5503).
34. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
35. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-1684.
36. Hoftijzer H, Heemstra KA, Morreau H et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161: 923-931.
37. Kober F, Hermann M, Handler A et al. Effect of Sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 2008; 26: (330s Abstr 6058).
38. Lam ET, Ringel MD, Kloos RT et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28: 2323-2330.
39. Ravaud A, de la Fouchardiere C, Courbon F. et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial 2009.
40. Cohen EE, Needles BM, Cullen KJ et al. Phase 2 study of sunitinib in refractory thyroid cancer. J.Clin.Oncol. 2009; 26 (Suppl): 6025.
41. Goulart B, Carr L, Martins RG et al. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastastic medullary thyroid carcinoma (MTC). Proc Am Soc Clin Oncol 2008; 26: 6062.
42. Frank-Raue K, Fabel M, Delorme S et al. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007; 157: 215-220.
43. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3466-3469.
44. Hoff PM, Hoff A.O., Phan A, et al. Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) with metastastatic medullary thyroid carcinomas (MTC). J Clin Oncol 2006; 24 (Suppl): 13048.
45. Bible KC, Smallridge RC, Maples WJ et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. Proc Am Soc Clin Oncol 2009; 27: 3521.
46. Kurzrock R, Cohen EE, Sherman SI et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL-184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2010; 28 (Suppl): 15s (Abstr 5502).
47. Flaherty KT, Puzanov I, Sosman J et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 9000).
48. Matsui J, Yamamoto Y, Funahashi Y et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008; 122: 664-671.
49. Matsui J, Funahashi Y, Uenaka T et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-5465.
50. Short SC, Suovuori A, Cook G et al. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 2004; 16: 569-574.
51. Coelho SM, Corbo R, Buescu A et al. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004; 27: 334-339.
52. Simon D, Koehrle J, Reiners C et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22: 569-574.
53. Simon D, Korber C, Krausch M et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002; 29: 775-782.
54. Simon D, Kohrle J, Schmutzler C et al. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996; 104 (Suppl 4): 13-15.
55. Zhang Y, Jia S, Liu Y et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 2007; 28: 251-255.
56. Liu YY, Stokkel MP, Pereira AM et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006; 154: 525-531.
57. Liu YY, Morreau H, Kievit J et al. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 2008; 158: 375-384.
58. Philips JC, Petite C, Willi JP et al. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun 2004; 25: 1183-1186.
59. Kebebew E, Peng M, Reiff E et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006; 140: 960-966.
60. Tepmongkol S, Keelawat S, Honsawek S et al. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008; 18: 697-704.
61. Venkataraman GM, Yatin M, Marcinek R et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999; 84: 2449-2457.
62. Kitazono M, Robey R, Zhan Z et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 3430-3435.
63. Furuya F, Shimura H, Suzuki H et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004; 145: 2865-2875.
64. Piekarz R, Luchenko V, Draper D et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. Proc Am Soc Clin Oncol 2008; 26 (20S): 3571.
65. Sherman E, Fury MG, Tuttle RM et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J Clin Oncol 2009; 27(Suppl): 15s (Abstr 6059).
66. Woyach JA, Kloos RT, Ringel MD et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodinerefractory thyroid carcinoma. J Clin Endocrinol Metab 2009; 94: 164-170.
67. Briere J, Pousset G, Darsy P et al. [The advantage of lithium in association with iodine 131 in the treatment of functioning metastasis of the thyroid cancer (author's transl)]. Ann Endocrinol (Paris) 1974; 35: 281-282.
68. Gershengorn MC, Izumi M, Robbins J. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol Metab 1976; 42: 105-111.
69. Koong SS, Reynolds JC, Movius EG et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 912-916.
70. Pons F, Carrio I, Estorch M et al. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 1987; 12: 644-647.
71. Spaulding SW, Burrow GN, Bermudez F et al. The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab 1972; 35: 905-911.
72. Liu YY, van der Pluijm G, Karperien M et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clin Endocrinol (Oxf) 2006; 64: 617-624.
73. Wang CY, Zhong WB, Chang TC et al. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003; 88: 3021-3026.
74. Zhong WB, Liang YC, Wang CY et al. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ ROCK signaling. Endocr Relat Cancer 2005; 12: 615-629.
75. Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 2005; 12: 291-303.
76. Mrozek E, Kloos RT, Ringel MD et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 2201-2204.
77. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007; 17: 663-670.
78. Ain KB, Lee C, Holbrook KM et al. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. Proc Am Soc Clin Oncol 2008; 26: 6027.
79. Mitsiades CS, McMillin D, Kotoula V et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006; 91: 4013-4021.
80. Conticello C, Adamo L, Giuffrida R et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 2007; 92: 1938-1942.
81. Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-3416.
82. Cooney MM, Savvides P, Agarwala S et al. Phase II study of combrestatin A4 phosphate (CA4P) in patients with advanced anaplstic thyroid carcinoma (ATC). J Clin Oncol 2006; 24: 300S.
83. Tabernero J, Schoffski P, Dirix L et al. Phase I study to determine the safety, pharmacology, and pharmacodynamics of JNJ-26854165 insubjects with advanced stage and/or refractory solid tumors 2008; EORTC-NCI-AACR Annual Meeting 2008 oral abstract 1592.
84. Marsee DK, Venkateswaran A, Tao H et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem 2004; 279: 43990-43997.
85. Yeung SC, Xu G, Pan J et al. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000; 60: 650-656.
86. Hong D, Camacho L, Ng C et al. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers. Proc Am Soc Clin Oncol 2007; 25 (18S): 3549.
87. Wells SA Jr, Gosnell JE, Gagel RF et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 2007; 25 18 (Suppl): 6018.
88. Kurzrock R, Sherman SI, Hong D et al. A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of patients with medullary thyroid cancer (MTC) Proceedings of 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 2008, Abstract 383, p. 119.
89. Spitzweg C. Gene therapy in thyroid cancer. Horm Metab Res 2009; 41: 500-509.
90. Papewalis C, Wuttke M, Seissler J et al. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin Cancer Res 2008; 14: 4298-4305.
91. Schott M, Feldkamp J, Klucken M et al. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 2002; 51: 663-668.
92. Schott M, Seissler J, Lettmann M et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 2001; 86: 4965-4969.
93. Postema PT, De Herder WW, Reubi JC et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996; 57 (Suppl 1): 36-37.
94. Krenning EP, Kwekkeboom DJ, Pauwels S et al. Somatostatin receptor scintigraphy. In Freeman, LM (ed): Nuclear Medicine Annual. New York: Lippincott Williams & Wilkins 1995; 1-50.
95. Valkema R, de JM, Bakker WH et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32: 110-122.
96. Gorges R, Kahaly G, Muller-Brand J et al. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001; 11: 647-659.
97. Waldherr C, Schumacher T, Pless M et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 2001; 22: 673-678.
98. Bodei L, Handkiewicz-Junak D, Grana C et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004; 19: 65-71.
99. Virgolini I, Britton K, Buscombe J et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32: 148-155.
100. Christian JA, Cook GJ, Harmer C. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid. Br J Cancer 2003; 89: 258-261.
101. Gabriel M, Froehlich F, Decristoforo C et al. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging 2004; 31: 330-341.
102. Teunissen JJ, Kwekkeboom DJ, Kooij PP et al. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 2005; 46 (Suppl 1): 107S-114S.
103. Stokkel MP, Verkooijen RB, Bouwsma H et al. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine nonresponsive thyroid cancer: a pilot study. Nucl Med Commun 2004; 25: 683-690.
104. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46 (Suppl 1): 67S-75S.
105. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009; 21: 296-303.